TRANSMEDICS GROUP INC (TMDX)
US89377M1099 - Common Stock
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Stocks that work for billionaires aren't necessarily appropriate for every investor.
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024
Wall Street analysts are rating these three long-term stocks as strong buys. Consider them for your portfolio.
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
Plan to buy these growth stocks since the market is significantly underpricing their potential for revenue upside over the next 18 months.
The 3 Most Promising MedTech Stocks to Invest In Now
MedTech stocks are often overlooked despite the inherent healthcare growth trajectory and industry-wide innovative spirit.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
2 Potentially Explosive Stocks to Buy in April
These two healthcare stocks should have plenty of room to run.
TransMedics Group (TMDX) Shares Cross Below 200 DMA
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
2 No-Brainer Growth Stocks to Buy With $100 in March
Find out why you could end up regretting not adding these stocks to your portfolio while they're so reasonably priced.
TMDX INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The healthcare sector is no slouch when it comes to top-performing growth stocks.
TransMedics to Present at Upcoming March Investor Conferences
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news affecting shares on Tuesday morning!
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
TransMedics Group GAAP EPS of $0.12 beats by $0.16, revenue of $81.2M beats by $12.7M (NASDAQ:TMDX)
TransMedics Group reports impressive Q4 earnings, beating expectations with a GAAP EPS of $0.12 and revenue of $81.2M, driven by increased utilization of...
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
Notable Monday Option Activity: TMDX, PAR, PPC
TransMedics Group Becomes Oversold (TMDX)
(NASDAQ:TMDX)
TransMedics Group is set to announce Q4 earnings on February 26th.
2 No-Brainer Growth Stocks You Can Buy With Less Than $100 and Hold at Least 5 Years
The businesses underlying these stocks have a lot of growing to do.